Renalytix (RENX) Proxy Filing summary

Executive summary

• A general meeting is scheduled for October 31, 2024, to vote on three key resolutions, including share issuances, a board appointment, and disapplication of pre-emption rights.

• The board unanimously recommends voting in favor of all resolutions, which are considered essential for the company's ongoing operations and capital needs.

• The net proceeds from the proposed fundraise are intended primarily for sales, marketing, and general corporate expenses.

• Voting is available electronically, by proxy, or via CREST/Proxymity, with specific deadlines for ordinary and ADS holders.

Voting matters and shareholder proposals

• Resolution 1 seeks authority to issue new shares and convertible bonds, raising approximately £11.8 million.

• Resolution 2 proposes the appointment of Julian Baines as a director, effective after the meeting.

• Resolution 3 requests disapplication of pre-emption rights for the new share and bond issuances.

• All resolutions require a majority, except Resolution 3, which needs 75% approval.

• Shareholders can submit proposals for the 2024 AGM if received by specified deadlines and thresholds.

Board of directors and corporate governance

• Julian Baines, with significant life sciences experience, is nominated for board appointment.

• Christopher Mills will remain as a non-executive director after stepping down as chairman.

• No family or material related-party relationships exist for the new nominee.